Nano-X Imaging (NASDAQ:NNOX) Posts Earnings Results, Misses Expectations By $0.35 EPS

Key Points

• Nano‑X missed earnings, reporting a ($0.50) EPS vs. a ($0.15) consensus (a $0.35 miss) on $3.72M revenue, with a GAAP net loss of $33.4M, a non‑GAAP loss of $11.2M, and about $60M in cash and marketable securities.
• Commercial push with caveats: the company announced a U.S. framework with Howard Technology to deploy 300 Nanox.ARC systems (60 in year one) plus roughly 360–400 additional systems, supporting a $35M 2026 revenue target, but deployment timing is uncertain due to import licenses, construction and regulatory constraints.
• Manufacturing restructuring: management closed the South Korea chip line, booked a $17.5M non‑cash impairment and is shifting production to outsourced partners to lower operating expenses and cash burn.

Nano-X Imaging (NASDAQ:NNOX - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.35), Zacks reports. The business had revenue of $3.72 million during the quarter, compared to analyst estimates of $3.99 million. Nano-X Imaging had a negative return on equity of 48.75% and a negative net margin of 680.11%.During the same quarter last year, the firm posted ($0.21) EPS.

Here are the key takeaways from Nano-X Imaging's conference call:

• Company announced a major U.S. framework with Howard Technology Solutions to deploy 300 Nanox.ARC systems over three years (60 in year one) and cited additional commercial agreements totaling roughly 360–400 systems, which management says underpins its $35M revenue target for 2026.
• Management initiated a manufacturing restructuring that closed the South Korea chip line and recorded a $17.5M non-cash impairment in Q4 2025, shifting production to outsourced partners (including Swiss partner System) to reduce OpEx and cash burn.
• Financial results showed a wider GAAP net loss of $33.4M in Q4 2025 (vs. $14.1M a year ago) and a non‑GAAP net loss of $11.2M, while revenue remained small at $3.7M; the balance sheet held about $60M in cash and marketable securities.
• Progress on regulatory, clinical, and AI fronts — including U.S. TAP2D clearance, updated AMAR approval in Israel, planned MDR submission, a Cedars‑Sinai trial for Nanox.AI, a U.S. IRB lung‑screening trial, and awards at RSNA/ECR — which management says strengthens clinical credibility and adoption potential.
• Management expects most revenue growth in the second half of 2026 but warns deployment timing remains constrained by import licenses, construction and regulatory processes; roughly 38 systems are at various deployment stages and ~15 installs are expected in the next few months, so revenue conversion timing is uncertain.

Nano-X Imaging Price Performance

Nano-X Imaging stock opened at $2.15 on Tuesday. The firm's 50 day simple moving average is $2.43 and its 200-day simple moving average is $3.05. The company has a market cap of $140.57 million, a P/E ratio of -1.63 and a beta of 1.39. Nano-X Imaging has a fifty-two week low of $2.11 and a fifty-two week high of $5.86.

Wall Street Analysts Forecast Growth

NNOX has been the subject of a number of recent research reports. Cantor Fitzgerald upgraded Nano-X Imaging to a "strong-buy" rating in a research report on Wednesday, March 4th. Weiss Ratings restated a "sell (e+)" rating on shares of Nano-X Imaging in a report on Friday, April 10th. Finally, D. Boral Capital reaffirmed a "buy" rating and set a $5.00 target price on shares of Nano-X Imaging in a research report on Monday. Three analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Buy" and an average price target of $5.00.

Institutional Investors Weigh In On Nano-X Imaging

Several hedge funds have recently made changes to their positions in the company. Aristides Capital LLC purchased a new position in Nano-X Imaging during the 4th quarter worth approximately $30,000. CIBC Bancorp USA Inc. purchased a new stake in shares of Nano-X Imaging in the third quarter valued at $40,000. Russell Investments Group Ltd. lifted its holdings in shares of Nano-X Imaging by 62.1% in the third quarter. Russell Investments Group Ltd. now owns 13,787 shares of the company's stock valued at $51,000 after purchasing an additional 5,283 shares in the last quarter. PharVision Advisers LLC acquired a new stake in shares of Nano-X Imaging in the third quarter worth $56,000. Finally, Mariner LLC boosted its position in shares of Nano-X Imaging by 70.5% in the fourth quarter. Mariner LLC now owns 20,825 shares of the company's stock worth $58,000 after buying an additional 8,614 shares during the period. Hedge funds and other institutional investors own 21.49% of the company's stock.

About Nano-X Imaging

Nano-X Imaging Ltd. is a medical technology company developing and commercializing a digital X-ray imaging platform designed to lower the cost and increase the accessibility of diagnostic imaging. Its flagship product, the Nanox.ARC, leverages a proprietary micro-electromechanical system (MEMS) based digital X-ray source and advanced image processing software to provide 2D and 3D imaging capabilities on a compact footprint. The system aims to streamline radiology workflows and facilitate point-of-care diagnostics in hospitals, clinics and outpatient settings.

The Nanox.ARC platform integrates a novel cold cathode X-ray source, which enables multiple emission points without the need for rotating anode tubes.